Subtype
Pancreatic Ductal Adenocarcinoma
CI-CAN-00008194PDA · PDACExplore in graph →
Loading cancer entity…
Subtype
CI-CAN-00008194PDA · PDACExplore in graph →
Variants & evidence
40 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| NRG1 Fusion + KRAS WildtypeNRG1KRAS1 | |||||||
| Afatinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7493Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC | civic |
| ATM R2034Ter1 | |||||||
| Olaparib | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID13230A 77 year old man with metastatic pancreatic ductal adenocarcinoma with somatic ATM R2034Ter mutation received off label olaparib after prior chemotherap. His disease remained stable for 18 months. PMID 40273902 · Vornhülz et al., 2025 · Open in CIViC | civic |
| NRG1 Fusion + KRAS WildtypeNRG1KRAS1 | |||||||
| Afatinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7492Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC | civic |
| CIP2A EXPRESSION1 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1117Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression … (full text at CIViC) PMID 26894380 · Xu et al., 2016 · Open in CIViC | civic |
| CIP2A Underexpression1 | |||||||
| Gemcitabine | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1118Researchers studied the effect of CIP2A expression in relation to gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicat… (full text at CIViC) PMID 26894380 · Xu et al., 2016 · Open in CIViC | civic |
| NTRK3 Fusion1 | |||||||
| (oncogenic) | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID10484Whole genome sequencing and RNAseq were performed on 400 patients with resected or locally advanced/metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Immunohistochemistry (IHC) analysis was performe… (full text at CIViC) PMID 34583947 · Allen et al., 2023 · Open in CIViC | civic |
| ERBB2 Amplification1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11563The ERRB2 amplification effect in PDAC was studied through CAPAN1 cells and ERBB2-KO (knockout) CAPAN1 cells that were KO using CRISPR (Figure 4C, Supp Table 4), with a 90% reduction of ERBB2 compared… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 E717D1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11555HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 L755S1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11557HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 L755S + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11558KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 Q679L1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11553HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 R678Q1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11551HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 R678Q + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11552KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S310F1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11547HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S423R1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11549HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L2 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11559HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| Neratinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11569Neratinib suppresses anchorage-independent growth in transduced HPNE cells with the variant in a concentration-dependent manner (Figure 6B–C) with complete inhibition at a concentration of 0.5 µM (Fig… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L + KRAS G12CERBB2KRAS1 | |||||||
| ARS-1620 + NeratinibCombination | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11572When tested in MIAPaCa2 (PDAC cell line and KRAS G12C) cells, Neratinib and ARS-1620 strongly inhibit AKT and MAPK phosphorylation (Figure 6F). Also, MIAPaCa2 cell line with the variant in exposure to… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V777L + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11560KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11561HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I1 | |||||||
| Neratinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11570Neratinib suppresses anchorage-independent growth in transduced HPNE cells with the variant in a concentration-dependent manner (Figure 6B–C) with complete inhibition at a concentration of 0.5 µM (Fig… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 V842I + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11562KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB3 EXPRESSION1 | |||||||
| 9F7-F11 + PertuzumabCombination | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID865In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC) PMID 25216528 · Thomas et al., 2014 · Open in CIViC | civic |
| FGFR3 K508M1 | |||||||
| (oncogenic) | Oncogenic | D | Does Not Support Oncogenicity | 2 | submitted | EID11798The study analysed the expression of the two splice variants of FGFR3 (FGFR3-IIIb and FGFR3-IIIc/FGFR3-IIIc-KD) in two pancreatic ductal adenocarcinoma cell lines (Capan-2 and BxPC-3). The FGFR3-IIIc-… (full text at CIViC) PMID 23902722 · Lafitte et al., 2013 · Open in CIViC | civic |
| NTRK1 Fusion1 | |||||||
| Entrectinib + LarotrectinibSequential | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID13049This case study reports a 78 year old patient with pancreatic adenocarcinoma harboring a GP2::NTRK1 gene fusion characterized by an in-frame rearrangement involving exon 2 of GP2 and exon 8 of NTRK1. … (full text at CIViC) PMID 42412359 · Tazuma et al., 2026 · Open in CIViC | civic |
| HSPB1 EXPRESSION1 | |||||||
| Gemcitabine | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID939HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine. PMID 22004109 · Schäfer et al., 2012 · Open in CIViC | civic |
| IDH1 R132H1 | |||||||
| Ivosidenib | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID5987A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed mol… (full text at CIViC) PMID 27466707 · Brody et al., 2018 · Open in CIViC | civic |
| ERBB2 V842I + KRAS G12CERBB2KRAS1 | |||||||
| ARS-1620 + NeratinibCombination | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11573When tested in MIAPaCa2 (PDAC cell line and KRAS G12C) cells, Neratinib and ARS-1620 strongly inhibit AKT and MAPK phosphorylation (Figure 6F). Also, MIAPaCa2 cell line with the variant in exposure to… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| KRAS G12D2 | |||||||
| Adebrelimab + KRAS G12D Inhibitor HRS-4642Combination | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13294In this phase 1/2 trial the KRAS G12D degrader HRS-4642 in combination with PD-L1 inhibitor adebrelimab was tested in 48 pretreated KRAS G12D-positive pancreatic adenocarcinoma patients. Patients had … (full text at CIViC) PMID 42748921 · Shi et al., 2026 · Open in CIViC | civic |
| Setidegrasib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12938A phase 1 dose‑escalation and dose‑expansion study in patients with previously treated advanced KRAS p.G12D mutant pancreatic ductal adenocarcinoma (NCT05382559; n = 203 overall; n = 21 PDAC treated a… (full text at CIViC) PMID 41879829 · Park et al., 2026 · Open in CIViC | civic |
| ERBB2 E717D + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11556KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 Q679L + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11554KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S310F + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11548KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| ERBB2 S423R + KRAS G12DERBB2KRAS1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11550KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC | civic |
| NQO1 Overexpression1 | |||||||
| NSC84167 | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID12560In preclinical pancreatic ductal adenocarcinoma (PDAC) models with high NQ01 expression, which indicates the NFE2L2 (NRF2) pathway activation, the small molecule NSC84167 (NSLC01, 50 mg/kg) selectivel… (full text at CIViC) PMID 34247201 · Dai et al., 2021 · Open in CIViC | civic |
| NR4A2 Overexpression1 | |||||||
| C-DIM 12 + GemcitabineCombination | Predictive | D | Supports Resistance | 3 | submitted | EID12649In pancreatic cancer cell lines MiaPaCa2 and Panc1, gemcitabine 1 μmol/L induced NR4A2/NURR1 expression and triggered cytoprotective autophagy, while both CRISPR-mediated NR4A2 knockout and the NR4A2 … (full text at CIViC) PMID 35582016 · Zarei et al., 2021 · Open in CIViC | civic |
| ATG12 Overexpression + ATG7 Overexpression + NR4A2 OverexpressionNR4A2ATG7ATG121 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12650In a retrospective TCGA PDAC (tumors n = 179, normals n = 171), high ATG7 expression was significantly associated with poorer survival on Kaplan–Meier analysis (P = 0.013), and high ATG12 expression s… (full text at CIViC) PMID 35582016 · Zarei et al., 2021 · Open in CIViC | civic |
| PALB2 Mutation1 | |||||||
| Talazoparib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID10835A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC) PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC | civic |
| SMAD4 Expression1 | |||||||
| (prognostic) | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1306In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC) PMID 11751510 · Tascilar et al., 2001 · Open in CIViC | civic |
| STK11 Loss1 | |||||||
| Roflumilast | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID12555In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC) PMID 38461159 · Zhang et al., 2024 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.